AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 184.03M | 677.30M | 291.68M | 0.41M | -4.62300M |
| Minority interest | 1.48M | 1.12M | - | - | - |
| Net income | 143.40M | 507.36M | 214.31M | 0.37M | -4.48900M |
| Selling general administrative | 111.07M | 50.73M | 15.21M | 6.41M | 5.54M |
| Selling and marketing expenses | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M |
| Gross profit | 366.90M | 777.05M | 331.90M | 18.42M | 10.66M |
| Reconciled depreciation | 32.66M | 1.71M | 2.96M | 2.11M | 2.16M |
| Ebit | 178.53M | 675.95M | 287.20M | -2.53500M | -7.22000M |
| Ebitda | 190.97M | 677.66M | 290.16M | -0.42800M | -5.05700M |
| Depreciation and amortization | 12.45M | 1.71M | 2.96M | 2.11M | 2.16M |
| Non operating income net other | - | 5.08M | -3.31600M | 0.06M | -0.50100M |
| Operating income | 178.53M | 675.95M | 290.16M | -0.42800M | -5.05700M |
| Other operating expenses | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M |
| Interest expense | 5.50M | 6.21M | 0.35M | 2.17M | 0.00000M |
| Tax provision | 42.10M | 174.79M | 72.53M | 0.04M | 0.04M |
| Interest income | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Net interest income | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 42.10M | 174.79M | 72.53M | 0.04M | -1.06900M |
| Total revenue | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M |
| Total operating expenses | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M |
| Cost of revenue | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M |
| Total other income expense net | 5.50M | 1.35M | 1.53M | 0.84M | 0.43M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 141.92M | 506.24M | 219.15M | -0.41100M | -5.60700M |
| Net income applicable to common shares | 143.40M | 507.36M | 214.31M | -0.41100M | -5.60700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1386.05M | 1278.72M | 700.46M | 88.76M | 55.02M |
| Intangible assets | 150.64M | 35.91M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 22.25M | -12.20600M | -16.49100M | 0.28M | 0.31M |
| Total liab | 116.18M | 112.84M | 131.07M | 5.98M | 2.75M |
| Total stockholder equity | 1269.88M | 1165.88M | 569.39M | 82.78M | 52.27M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 58.35M | 36.69M | 62.72M | 3.61M | 1.43M |
| Common stock | 0.00300M | 0.00300M | 0.00300M | 0.00200M | 0.00200M |
| Capital stock | 0.00300M | 0.00300M | 0.00300M | 0.00200M | 0.00200M |
| Retained earnings | 801.00M | 657.60M | 150.88M | -63.42900M | -63.01800M |
| Other liab | 17.46M | 0.79M | 0.39M | - | 0.01M |
| Good will | 143.03M | 50.90M | - | - | - |
| Other assets | 26.56M | 912.63M | 44.54M | 0.25M | 0.02M |
| Cash | 79.51M | 164.89M | 87.43M | 11.96M | 6.74M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 116.18M | 112.84M | 131.07M | 5.98M | 2.75M |
| Current deferred revenue | 14.09M | 34.38M | 26.58M | 0.36M | - |
| Net debt | -58.86800M | -143.61000M | -71.57200M | -9.28900M | -6.73600M |
| Short term debt | 20.64M | 21.28M | 15.29M | 0.42M | - |
| Short long term debt | 20.64M | 21.28M | 15.02M | - | - |
| Short long term debt total | 20.64M | 21.28M | 15.85M | 2.68M | - |
| Other stockholder equity | 477.39M | 487.07M | 418.06M | 146.06M | 114.20M |
| Property plant equipment | 98.92M | 62.29M | 40.20M | 8.61M | 6.45M |
| Total current assets | 905.63M | 1074.46M | 615.73M | 76.77M | 43.37M |
| Long term investments | 339.03M | 507.01M | 132.50M | 42.82M | 7.90M |
| Net tangible assets | 973.01M | 1165.88M | 569.39M | 82.78M | 51.15M |
| Short term investments | 773.38M | 770.65M | 344.44M | 58.25M | 30.68M |
| Net receivables | 52.75M | 138.91M | 183.86M | 6.55M | 5.95M |
| Long term debt | - | - | - | - | - |
| Inventory | 4.28M | 12.21M | 16.49M | 0.28M | 0.31M |
| Accounts payable | 23.09M | 20.49M | 26.49M | 1.58M | 1.31M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 7.13M | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -20.90300M | -0.75900M | 0.44M | 0.15M | -0.03500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00300M | 0.00300M | 0.00200M | 0.00200M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 657.60M | 150.88M | -63.42900M | -63.01800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -233.63500M | 141.97M | -87.96600M | -36.80800M | -2.70300M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 480.42M | 204.26M | 84.73M | 11.98M | 11.64M |
| Capital lease obligations | - | - | 0.83M | 2.68M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -261.31400M | -460.89900M | -289.93600M | -27.86400M | 3.27M |
| Change to liabilities | -25.33900M | -12.20600M | 108.57M | -0.04100M | 0.64M |
| Total cashflows from investing activities | -261.31400M | -546.54800M | -326.43800M | -29.04600M | 0.95M |
| Net borrowings | -1.06700M | -0.01100M | 15.02M | 15.02M | 15.02M |
| Total cash from financing activities | -77.14100M | 85.41M | 261.25M | 28.77M | 0.01M |
| Change to operating activities | -40.46700M | 19.76M | 11.12M | 0.23M | 0.62M |
| Net income | 141.92M | 506.24M | 214.31M | -0.41100M | -5.60700M |
| Change in cash | -85.38800M | 77.47M | 75.46M | 5.23M | 0.25M |
| Begin period cash flow | 164.89M | 87.43M | 11.96M | 6.74M | 6.49M |
| End period cash flow | 79.51M | 164.89M | 87.43M | 11.96M | 6.74M |
| Total cash from operating activities | 253.52M | 538.58M | 140.63M | 5.52M | -0.67500M |
| Issuance of capital stock | 0.00000M | 89.47M | 246.19M | 28.76M | - |
| Depreciation | 32.66M | 11.00M | 2.96M | 2.11M | 2.16M |
| Other cashflows from investing activities | - | -81.83700M | -1.37200M | -27.86400M | 3.27M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | -36.18100M |
| Change to account receivables | 68.64M | 42.30M | -178.48000M | -0.83900M | -1.97000M |
| Sale purchase of stock | -74.33700M | 89.57M | -0.06200M | -0.02100M | 0.01M |
| Other cashflows from financing activities | -1.76800M | -4.05900M | 15.12M | 0.04M | 0.01M |
| Change to netincome | 75.45M | 22.89M | 8.72M | 4.22M | 3.72M |
| Capital expenditures | 18.77M | 23.84M | 36.51M | 1.32M | 2.83M |
| Change receivables | - | 42.30M | -178.48000M | -0.83900M | -1.97000M |
| Cash flows other operating | - | 4.45M | -16.30800M | 0.38M | 0.09M |
| Exchange rate changes | - | - | - | - | -0.04400M |
| Cash and cash equivalents changes | - | 77.43M | 75.44M | 5.25M | 0.25M |
| Change in working capital | 2.00M | -2.67600M | -91.45100M | -0.91500M | -1.24400M |
| Stock based compensation | 32.64M | 15.88M | 8.16M | 3.21M | 2.30M |
| Other non cash items | 43.46M | 15.97M | 8.05M | 1.55M | 1.67M |
| Free cash flow | 234.75M | 514.73M | 104.12M | 4.20M | -3.50700M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FLGT Fulgent Genetics Inc |
-0.71 3.42% | 20.03 | - | 7.94 | 2.92 | 0.64 | 1.18 | -6.5565 |
| TMO Thermo Fisher Scientific Inc |
-5.66 0.98% | 571.73 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-4.61 1.84% | 245.80 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| IDXX IDEXX Laboratories Inc |
-5.02 1.02% | 489.24 | 55.57 | 53.76 | 12.50 | 34.56 | 12.72 | 38.21 |
| IQV IQVIA Holdings Inc |
-6.86 2.85% | 233.98 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
4978 Santa Anita Avenue, Temple City, CA, United States, 91780
| Name | Title | Year Born |
|---|---|---|
| Mr. Ming Hsieh | Chairman & CEO | 1956 |
| Mr. Jian Xie | COO & Pres | 1966 |
| Mr. Paul Kim | Chief Financial Officer | 1967 |
| Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D. | Chief Scientific Officer & Laboratory Director | 1967 |
| Ms. Natalie Prescott | VP of Legal & Deputy Gen. Counsel | NA |
| Ms. Doreen Ng | VP of Operations & Compliance and GM of Houston Office | NA |
| Mr. Jakub Sram | VP of Bus. Devel. & Sales | NA |
| Ms. Ellen Tsui | VP of HR | NA |
| Mr. Brandon Perthuis | Chief Commercial Officer | NA |
| Dr. Lawrence M. Weiss M.D. | Chief Medical Officer | 1957 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...